Abstract
Background: Vitiligo is a common depigmentation disorder occurring in about 1% of the population worldwide. The disease causes the appearance of white patches on the skin. If vitiligo involves most of the body, it might be easier to depigment the normal remaining skin rather than to attempt repigmentation. For depigmentation therapy, monobenzyl ether of hydroquinone (MBEH) remains the only drug that the Food and Drug Administration approved for depigmentation therapy within the United States. The mechanism of toxicity of MBEH has remained little understood.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have